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We read with interest ‘Treatment-related mortality with
aflibercept in cancer patients” by Wei-Xiang Qi and col-
leagues in the April 2014 issue of your journal [1], in which
they conclude that the use of aflibercept is associated with an
increased risk of fatal adverse events (FAEs) compared with
controls. It is our opinion that this meta-analysis has some
important methodological flaws.
The analysis was conducted using the published data
for 3,060 patients, with a range of solid tumors. In 954
patients who received single-agent aflibercept and had
data available for analysis, the authors estimated the
overall incidence of FAEs to be 5.1 % (95 % CI 3.8–
6.8) [1]. However, the authors erroneously included the
VENICE trial [2] in their estimate of the incidence of
FAEs with single-agent aflibercept. The phase III
VENICE trial compared docetaxel and prednisone plus
either aflibercept or placebo for the treatment of meta-
static castration-resistant prostate cancer and therefore is
not informative for single-agent aflibercept. Also, in the
VENICE trial, the aflibercept dose was 6 mg/kg and not
the 4 mg/kg dose approved for use in patients with
metastatic colorectal cancer (mCRC) who have
progressed on prior oxaliplatin-containing therapy.
Another important point is that the methodology used
for calculating the incidence of FAEs may be inappro-
priate. By using the logit transformation (extremely un-
usual when estimating a single proportion), the authors
implicitly assigned weights that were not proportional to
the number of patients. Consequently, studies with high
FAE rates are over-weighted. The exclusion of the
VENICE trial and the subsequent assignment of appro-
priate weights result in an estimate of the incidence of
FAEs of 3.2 % (95% CI 1.6–5.6) for single-agent
aflibercept.
Also, in an attempt to determine the specific contri-
bution of aflibercept to the development of FAEs, the
authors calculated the odds ratio (OR) for FAEs from
four randomized clinical trials comparing aflibercept
with controls in 2,715 patients. Most surprisingly, they
excluded from their analysis the pivotal, randomized,
VELOUR trial, in patients with mCRC who were resis-
tant to or had progressed on a prior oxaliplatin-
containing regimen [3], which led to the only approved
indication for aflibercept. Furthermore, the authors ex-
tracted incorrect FAE values for the phase III VITAL
study [4]. The correct values for FAEs in the VITAL
study [4] are 32 FAEs in the aflibercept group versus
18 in the control group, and not 11 versus 1. For all
FAE recalculations that included the VITAL study, we
used the data from the referenced publication.
Inclusion of the VELOUR study in the estimates of
FAEs results in an OR of 1.516 (95 % CI 1.124–2.053,
one-sided p=0.0028). Taking into account only the stud-
ies using the approved 4 mg/kg dose and including the
pivotal VELOUR study [3], the OR is 1.289 (95 % CI
0.836–2.001, one-sided p=0.1354), corresponding to
an increased risk of FAEs of approximately 29 %. For
the two randomized controlled trials using the higher
6 mg/kg dose of aflibercept (2,137 patients) [2, 4],
the OR is 1.767 (95 % CI 1.156–2.734, one-sided
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p=0.0037), corresponding to an increase in the relative
risk of FAEs of 77 %.
We would like to reiterate that in this meta-analysis,
the studies used to estimate the incidence of FAEs with
aflibercept in cancer patients are all outside the labeled
indication for aflibercept. Also, the exclusion of the
VELOUR trial renders the results of this meta-analysis
incomplete and prone to misinterpretation, although the
authors conclude that the use of aflibercept remains
justified in its approved indication in patients with
mCRC. Importantly, and as reported previously for
VELOUR [3] and other clinical studies [5], the safety
profile associated with combining aflibercept with che-
motherapy is similar to that seen with other anti-VEGF
agents, with no new toxicity signals observed.
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